ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/WA/6009-Nedlands-One-Clinical-Research
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
42
trial(s) found.
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
BGB-11417-302
)
BCL2 inhibitor
BTK inhibitor
placebo
B-cell lymphoma
Mantle cell lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06650566
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (
LM299-01-102
)
bispecific PD-1/VEGF antibody
Cancer
WA
6009 - Nedlands - One Clinical Research
NCT06623422
Curative
Phase 3
Recruiting
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (
V940-009
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - One Clinical Research
NCT06596473
Advanced
Phase 1
Recruiting
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors (
BG-C477-101
)
anti-CEACAM5 antibody-drug conjugate
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06422520
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors (
BGB-C354-101
)
anti-B7H3 antibody-drug conjugate
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NCT06345729
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50% (
1084-004
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06305767
Curative
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005) (
V940-005
)
anti-NECTIN4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Bladder cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06190951
Curative
Phase 2
Recruiting
A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma (
R3767-ONC-2208
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06077760
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (
INTerpath-002
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05730036
Haem
Phase 3
Recruiting
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (
LINKER-MM3
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT05607498
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma (
EMB07X101
)
bispecific PD-L1/OX40 antibody
bispecific T-cell engager,ROR1-targeting
Lymphoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05533697
Advanced
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (
mRNA-4359-P101
)
mRNA personalised cancer vaccine,IDO/PD-L1-targeting
Solid tumour
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2228 - Miranda - Southside Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05512390
Haem
Phase 1
Recruiting
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies (
M22-716
)
anti-CD19 antibody-drug conjugate,glucocorticoid receptor modulator
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NCT05498597
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours (
AMT-151-01
)
anti-FR-alpha antibody-drug conjugate
Adenocarcinoma
Cancer
Carcinoma
Endometrial cancer
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Lung adenocarcinoma
Ovarian cancer
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Pancreatic adenocarcinoma
Pleural mesothelioma
Solid tumour
Triple-negative breast cancer
Uterine serous carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05468697
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (
6482-024
)
CDK4/6 inhibitor
HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05315700
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Study of ORIC-114 As a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (
ORIC-114-01
)
EGFR inhibitor,exon 20 selective
ERBB2 inhibitor,exon 20 selective
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05309421
Advanced
Phase 2
Recruiting
An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma (
EVX-01-001
)
anti-PD-1 monoclonal antibody
autologous anticancer vaccine
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
WA
6009 - Nedlands - One Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05277168
Advanced
Phase 1 / Phase 2
Recruiting
AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS (
SHR-A1904-I-104
)
anti-CLDN18.2 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Sydney South West Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Gold Coast Private Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05205109
Advanced
Phase 1
Recruiting
A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (
ATG-037-001
)
CD73 inhibitor
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - One Clinical Research
NCT05199753
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours (
LM108-01-101
)
anti-CCR8 monoclonal antibody
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05170204
Curative
Phase 3
Recruiting
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (
BO42777
)
ALK/RET inhibitor
ALK inhibitor
ALK inhibitor,second generation
ALK inhibitor,third generation
Alectinib
Durvalumab
Entrectinib
RET inhibitor
ROS1 inhibitor
TRK inhibitor
TRK inhibitor,first generation
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,TRK-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04923048
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ⅰ/Ⅱ, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (
GB261-001
)
bispecific T-cell engager,CD20-targeting
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital (TERMINATED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
BCL2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04735575
Haem
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma (
EMB06X101
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
VIC
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
WA
6009 - Nedlands - One Clinical Research
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT03313778
Curative
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (
KEYNOTE-603
)
mRNA personalised cancer vaccine
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06295809
Curative
Phase 2 / Phase 3
Active not recruiting
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007). (
V940-007
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Carcinoma
Skin cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05933577
Curative
Phase 3
Active not recruiting
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001) (
V940-001
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05665595
Curative
Phase 3
Active not recruiting
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010) (
7684A-010
)
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Tasman Oncology
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT05635708
Advanced
Phase 2
Active not recruiting
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (
BGB-LC-201
)
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2086 - Frenchs Forest - Northern Beaches Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - One Clinical Research
NCT05609370
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (
BGB-A317-LBL-007-201
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2650 - Wagga Wagga - Riverina Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT05608291
Curative
Phase 3
Active not recruiting
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma (
R3767-ONC-2055
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT05583552
Haem
Phase 2
Active not recruiting
A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy (
IMpress
)
telomerase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05487235
Advanced
Phase 1
Not recruiting
A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (
GO43712
)
SHP2 inhibitor
anti-PD-L1 monoclonal antibody
Head and neck squamous cell carcinoma
Melanoma
NOT Mucosal melanoma
NOT Uveal melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05480865
Advanced
Phase 1
Terminated
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (
Argonaut
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
SHP2 inhibitor
Non-small cell lung cancer
Solid tumour
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - One Clinical Research
NCT05419388
Advanced
Phase 1 / Phase 2
Not recruiting
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (
BP43963
)
bispecific PD-1/LAG3 antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05254743
Haem
Phase 3
Active not recruiting
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
BRUIN-CLL-314
)
BTK inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Small Lymphocytic Lymphoma
NA
2025 - Papatoetoe - Middlemore Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - One Clinical Research
NZ
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT05210790
Haem
Phase 3
Active not recruiting
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera (
VERIFY
)
hepcidin mimetic
Polycythemia vera
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05200013
Advanced
Phase 1
Completed
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients With Advanced Solid Tumours (
BAT-7104-002-CR
)
bispecific PD-L1/CD47 antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04861779
Advanced
Phase 1
Unknown
A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy (
HSK29116-101
)
BTK PROTAC degrader
B-cell malignancy
WA
6009 - Nedlands - One Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (28)
Active not recruiting (9)
Not recruiting (2)
Terminated (1)
Completed (1)
Unknown (1)
Recruitment Country and State
WA (42)
VIC (35)
NSW (34)
QLD (18)
SA (15)
NZ (13)
TAS (2)
Phase
Phase 1 (11)
Phase 1 / Phase 2 (15)
Phase 2 (4)
Phase 2 / Phase 3 (1)
Phase 3 (11)
Trial Type
Advanced (23)
Curative (10)
Haem (9)
Cancer Therapy Class
PD-1/PD-L1
57%
PD-1
48%
LAG3
12%
PD-L1
12%
BTK
7%
BCL2
5%
VEGF
5%
KRAS
5%
KRAS G12C
5%
BCMA
5%
OX40
5%
CCR8
5%
SHP2
5%
CEACAM5
2%
Trop2
2%
B7H3
2%
NECTIN4
2%
CS1
2%
cereblon
2%
ROR1
2%
IDO
2%
CD19
2%
FR-alpha
2%
CDK4
2%
CDK6
2%
HIF2a
2%
EGFR
2%
ERBB2
2%
CLDN18.2
2%
CD73
2%
ALK
2%
RET
2%
ROS1
2%
TRK
2%
CD20
2%
DNA methyltransferase
2%
TP53
2%
TP53 Y220C
2%
TIGIT
2%
HPK1
2%
telomerase
2%
HRAS G12C
2%
NRAS G12C
2%
CD47
2%
Facility
6009 - Nedlands - One Clinical Research (42)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (10)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (10)
3004 - Melbourne, Southbank - Alfred Health (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (8)
3199 - Frankston - Peninsula Health Frankston Hospital (8)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (8)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (7)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
3065 - Fitzroy - St Vincent's Hospital Melbourne (5)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (5)
3168 - Clayton - Monash Medical Centre (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2109 - North Ryde - Macquarie University Hospital (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (4)
5042 - Bedford Park - Flinders Medical Centre (4)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
2139 - Concord - Concord Repatriation General Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
NZ.9016 - Dunedin - Dunedin Hospital (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
6005 - West Perth - Perth Blood Institute (2)
6009 - Nedlands - Linear Clinical Research (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
4215 - Southport - Tasman Oncology (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
4217 - Benowa - Pindara Private Hospital (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
2170 - Liverpool - Liverpool Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
6168 - Cooloongup - Rockingham Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3066 - Epping - Northern Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2170 - Liverpool - Sydney South West Private Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4215 - Southport - Gold Coast Private Hospital (1)
2217 - Kogarah - St George Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
3199 - Frankston - PASO Medical (1)
4870 - Cairns - Cairns Base Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2650 - Wagga Wagga - Riverina Cancer Care Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2025 - Papatoetoe - Middlemore Hospital
3021 - St Albans - Western Health - Sunshine Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Melanoma
Gastrointestinal cancer
B-cell malignancy
Lymphoma
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
Leukaemia
B-cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Breast adenocarcinoma
Breast cancer
Carcinoma
Gynaecological cancer
Ovarian cancer
Triple-negative breast cancer
Head and neck cancer
Myeloproliferative neoplasm
Bladder cancer
Multiple myeloma
Plasma cell disorder
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Endometrial cancer
Clear cell renal cell carcinoma
Kidney cancer
Head and neck squamous cell carcinoma
Acute myeloid leukaemia
Myelodysplastic syndrome
Myeloid leukaemia
Mantle cell lymphoma
Biliary tract cancer
Hepatobiliary cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Adenocarcinoma
Endometrial adenocarcinoma
Endometrial carcinoma
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Epithelial Ovarian Cancer
Lung adenocarcinoma
Mesothelioma
Non-squamous non-small-cell lung cancer
Ovarian adenocarcinoma
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Pleural mesothelioma
Uterine serous carcinoma
Cervical cancer
Colorectal adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
HPV-related cancer
HPV16-positive cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Oesophageal cancer
Urothelial carcinoma
Viral-related cancer
Myelodysplastic/Myeloproliferative disease
HER2-negative breast cancer
HER2-positive breast cancer
Male genital cancers
Neuroendocrine carcinoma
Prostate cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Skin cancer
Small Lymphocytic Lymphoma
Polycythemia vera
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy